Comments on news about the license on a long-acting technology platform published this Monday
Ascendis Pharma, a prodrug technology platform company announced yesterday that they have signed a license agreement with Novo Nordisk. “Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases”. “A once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate”.
It is and has been expected that Novo Nordisk evaluates multiple candidates for transforming typ-2 diabetes and obesity treatments to less frequent dosing. It was also clear last week at the PODD (Partnering opportunities in Drug Delivery) conference that there is a clear global trend towards less frequent dosing in the GLP-1 area, so realistically there will be parallel developments using different technologies ongoing, and we expect several technologies will eventually reach the market in this gigantic and fast-growing area. Referring again to the PODD conference and the ongoing BIO-Europe conference, it is also very clear that we have several companies interested in our PharmaShell technology for the use to develop long-acting GLP-1 products and others.
“Our feasibility program with Novo Nordisk continues as planned and we predict we will be successful in reaching the targets agreed within the timeframe of their exclusivity” says David Westberg CEO of Nanexa.
